Literature DB >> 21606428

Rectal cancer trials: no movement.

Martin R Weiser.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21606428     DOI： 10.1200/JCO.2011.35.7053

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  PACE Continuous Innovation Indicators-a novel tool to measure progress in cancer treatments.

Authors:  Silvia Paddock; Lauren Brum; Kathleen Sorrow; Samuel Thomas; Susan Spence; Catharina Maulbecker-Armstrong; Clifford Goodman; Michael Peake; Gordon McVie; Gary Geipel; Rose Li
Journal:  Ecancermedicalscience       Date:  2015-01-07

2.  Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.

Authors:  Ramon Salazar; Matilde Navarro; Ferran Losa; Vicente Alonso; Manel Gallén; Fernando Rivera; Manuel Benavides; Pilar Escudero; Encarnación González; Bartomeu Massutí; Auxiliadora Gómez; Margarita Majem; Enrique Aranda
Journal:  Clin Transl Oncol       Date:  2012-07-11       Impact factor: 3.405

3.  Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.

Authors:  Manuel de las Heras; Fernando Arias; Rosario del Moral-Avila; Jaime Gómez-Millán; Encarnación Jiménez; Amadeo Wals; Jose Luis Tisaire; Ma Pino Alcantara
Journal:  Clin Transl Oncol       Date:  2012-08-02       Impact factor: 3.405

4.  Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Authors:  Marie Grøn Saelen; Anne Hansen Ree; Alexandr Kristian; Karianne Giller Fleten; Torbjørn Furre; Helga Helseth Hektoen; Kjersti Flatmark
Journal:  Radiat Oncol       Date:  2012-09-27       Impact factor: 3.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.